Anindita Nayak
Bhubaneswar, 26 Jan 2026
The share price of Dr. Reddy’s Laboratories increased around 5.5% last week in NSE on the back of a better performance in Q3FY26. The company showed strong growth within the Indian and Emerging Market (EM) markets, along with a resilient branded business performance. Favourable foreign exchange (FX) gains also supplemented its growth.
Snapshot of Q3 FY26 Financial Performance:
| Particulars | Q3 FY26 (₹ Crore) | Rise/Fall (YoY) |
| Revenue | ₹8,726.8 | 4.4% ↑ |
| Gross Margin (%) | 53.6% | 505 bps ↓ |
| Net Income (PAT) | ₹1,209.8 | 14.4% ↓ |
| Diluted EPS | ₹14.52 | 14.3% ↓ |
Performance by Geography and Segment:
| Metric | Q3 FY26 (₹ Crore) | Rise/Fall YoY |
| India Business | ₹1,603.2 | 19% ↑ |
| Emerging Markets | ₹1,896.1 | 32% ↑ |
| Europe | ₹1,447.6 | 20% ↑ |
| North America | ₹2,964.4 | 12% ↓ |
| PSAI Segment | ₹801.8 | 2% ↓ |
Performance by Technology and Pipeline Highlights:
| Metric | Q3 FY26 | Rise/Fall YoY |
| Global Generics Revenue | ₹7,911.3 Crore | 7% ↑ |
| R&D Expenditure | ₹614.9 Crore | 8% ↓ |
